SRC
SRC proto-oncogene, non-receptor tyrosine kinase, the group of Src family tyrosine kinases|SH2 domain containing
Basic information
Region (hg38): 20:37344685-37406050
Previous symbols: [ "SRC1" ]
Links
Phenotypes
GenCC
Source:
- colorectal cancer (No Known Disease Relationship), mode of inheritance: Unknown
- thrombocytopenia 6 (Supportive), mode of inheritance: AD
- thrombocytopenia 6 (Limited), mode of inheritance: AD
- thrombocytopenia 6 (Moderate), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Thrombocytopenia, autosomal dominant, 6 | AD | Hematologic | Individuals have been described with bleeding diathesis, including after dental/surgical procedures, and awareness may allow preventive measures and prompt treatment | Hematologic; Musculoskeletal | 26936507 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SRC gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
|---|---|---|---|---|---|---|
| synonymous | 12 | 18 | ||||
| missense | 13 | 15 | ||||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| inframe indel | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| splice region | 1 | 1 | ||||
| non coding | 21 | 23 | ||||
| Total | 0 | 1 | 14 | 14 | 27 |
Variants in SRC
This is a list of pathogenic ClinVar variants found in the SRC region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
| Position | Type | Phenotype | Significance | ClinVar |
|---|---|---|---|---|
| 20-37384165-C-T | not provided (-) | |||
| 20-37384214-G-A | not provided (-) | |||
| 20-37384238-G-T | not provided (-) | |||
| 20-37384614-A-G | Benign (Jun 19, 2021) | |||
| 20-37384620-A-G | Benign (Jun 19, 2021) | |||
| 20-37384622-A-G | Benign (Jun 19, 2021) | |||
| 20-37384626-A-G | Benign (Jun 19, 2021) | |||
| 20-37384638-T-G | Benign (Jun 19, 2021) | |||
| 20-37384640-A-T | Benign (Jun 19, 2021) | |||
| 20-37384641-T-G | Benign (Jun 19, 2021) | |||
| 20-37384646-T-C | Benign (Jun 19, 2021) | |||
| 20-37384650-A-G | Benign (Jun 19, 2021) | |||
| 20-37384652-T-G | Benign (Jun 19, 2021) | |||
| 20-37384660-T-G | Benign (Jun 19, 2021) | |||
| 20-37384662-A-G | Benign (Jun 19, 2021) | |||
| 20-37384666-CAAGA-C | Benign (Jun 19, 2021) | |||
| 20-37384673-A-AG | Benign (Jun 19, 2021) | |||
| 20-37384677-A-G | Benign (Jun 19, 2021) | |||
| 20-37384686-C-CG | Benign (Jun 19, 2021) | |||
| 20-37384700-T-C | Benign (Jun 19, 2021) | |||
| 20-37384707-CT-C | Benign (Jun 19, 2021) | |||
| 20-37386120-C-T | not specified | Uncertain significance (Jan 10, 2023) | ||
| 20-37386151-G-T | not specified | Uncertain significance (Jan 23, 2023) | ||
| 20-37393931-A-G | Benign (Aug 20, 2018) | |||
| 20-37393967-G-A | Likely benign (Mar 01, 2024) |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| SRC | protein_coding | protein_coding | ENST00000373578 | 11 | 61366 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.997 | 0.00309 | 125652 | 0 | 2 | 125654 | 0.00000796 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 3.87 | 129 | 326 | 0.396 | 0.0000209 | 3405 |
| Missense in Polyphen | 48 | 181.22 | 0.26487 | 1831 | ||
| Synonymous | 0.866 | 135 | 148 | 0.910 | 0.0000104 | 1076 |
| Loss of Function | 4.34 | 2 | 25.8 | 0.0775 | 0.00000120 | 306 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.00 | 0.00 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.00000903 | 0.00000880 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.0000327 | 0.0000327 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein- coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN) (Probable). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN) (PubMed:21411625). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta- catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1 (Probable). Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors (By similarity). Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1 (PubMed:11389730). Plays a role in EGF-mediated calcium-activated chloride channel activation (PubMed:18586953). Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of GRK2, leading to beta-arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor (Probable). Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus (PubMed:7853507). Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function (PubMed:8755529, PubMed:14585963). Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase (PubMed:12615910). Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation (PubMed:16186108). Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731' (PubMed:20100835, PubMed:21309750). Enhances DDX58/RIG-I-elicited antiviral signaling (PubMed:19419966). Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376' (PubMed:14585963). Phosphorylates BCAR1 at 'Tyr-128' (PubMed:22710723). Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3 activity (PubMed:20525694). Involved in anchorage-independent cell growth (PubMed:19307596). Required for podosome formation (By similarity). {ECO:0000250|UniProtKB:P05480, ECO:0000269|PubMed:11389730, ECO:0000269|PubMed:12615910, ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:16186108, ECO:0000269|PubMed:18586953, ECO:0000269|PubMed:19307596, ECO:0000269|PubMed:19419966, ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:21309750, ECO:0000269|PubMed:21411625, ECO:0000269|PubMed:22710723, ECO:0000269|PubMed:7853507, ECO:0000269|PubMed:8755529, ECO:0000269|PubMed:8759729, ECO:0000305|PubMed:11964124, ECO:0000305|PubMed:8672527, ECO:0000305|PubMed:9442882}.;
- Disease
- DISEASE: Note=SRC kinase activity has been shown to be increased in several tumor tissues and tumor cell lines such as colon carcinoma cells. {ECO:0000269|PubMed:2498394, ECO:0000269|PubMed:3093483}.; DISEASE: Thrombocytopenia 6 (THC6) [MIM:616937]: A form of thrombocytopenia, a hematologic disorder defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. THC6 is an autosomal dominant form. Affected individuals may also have bone abnormalities and an increased risk for myelofibrosis. {ECO:0000269|PubMed:26936507}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Inflammatory mediator regulation of TRP channels - Homo sapiens (human);Platelet activation - Homo sapiens (human);Focal adhesion - Homo sapiens (human);Relaxin signaling pathway - Homo sapiens (human);Oxytocin signaling pathway - Homo sapiens (human);Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human);VEGF signaling pathway - Homo sapiens (human);GABAergic synapse - Homo sapiens (human);Adherens junction - Homo sapiens (human);Bladder cancer - Homo sapiens (human);Endocytosis - Homo sapiens (human);Tight junction - Homo sapiens (human);GnRH signaling pathway - Homo sapiens (human);ErbB signaling pathway - Homo sapiens (human);Gap junction - Homo sapiens (human);Chemokine signaling pathway - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);Mitophagy - animal - Homo sapiens (human);Epithelial cell signaling in Helicobacter pylori infection - Homo sapiens (human);Axon guidance - Homo sapiens (human);Thyroid hormone signaling pathway - Homo sapiens (human);Estrogen signaling pathway - Homo sapiens (human);Fluid shear stress and atherosclerosis - Homo sapiens (human);C-type lectin receptor signaling pathway - Homo sapiens (human);Tuberculosis - Homo sapiens (human);Rap1 signaling pathway - Homo sapiens (human);Bacterial invasion of epithelial cells - Homo sapiens (human);Shigellosis - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);Prolactin signaling pathway - Homo sapiens (human);Viral carcinogenesis - Homo sapiens (human);Hepatitis B - Homo sapiens (human);Beta-agonist/Beta-blocker Pathway, Pharmacodynamics;Androgen receptor signaling pathway;Angiogenesis;Angiogenesis overview;RANKL-RANK (Receptor activator of NFKB (ligand)) Signaling Pathway;Integrin-mediated Cell Adhesion;Leptin signaling pathway;Human Thyroid Stimulating Hormone (TSH) signaling pathway;Follicle Stimulating Hormone (FSH) signaling pathway;Prolactin Signaling Pathway;Regulation of Microtubule Cytoskeleton;Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway;Signaling Pathways in Glioblastoma;AGE-RAGE pathway;Interleukin-11 Signaling Pathway;Oncostatin M Signaling Pathway;Brain-Derived Neurotrophic Factor (BDNF) signaling pathway;Alpha 6 Beta 4 signaling pathway;Integrated Lung Cancer Pathway;Polycystic Kidney Disease Pathway;Aryl Hydrocarbon Receptor;JAK-STAT;IL-3 Signaling Pathway;Aryl Hydrocarbon Receptor Pathway;Pregnane X Receptor pathway;Nuclear Receptors Meta-Pathway;Kit receptor signaling pathway;Focal Adhesion;Signaling of Hepatocyte Growth Factor Receptor;Rac1-Pak1-p38-MMP-2 pathway;TGF-beta Signaling Pathway;Amplification and Expansion of Oncogenic Pathways as Metastatic Traits;Association Between Physico-Chemical Features and Toxicity Associated Pathways;VEGFA-VEGFR2 Signaling Pathway;Robo4 and VEGF Signaling Pathways Crosstalk;Liver steatosis AOP;Fibrin Complement Receptor 3 Signaling Pathway;MET in type 1 papillary renal cell carcinoma;EGF-EGFR Signaling Pathway;EPO Receptor Signaling;Notch Signaling Pathway;Senescence and Autophagy in Cancer;ErbB Signaling Pathway;Developmental Biology;Negative regulation of FGFR2 signaling;Signaling by FGFR2;RUNX2 regulates osteoblast differentiation;MAP2K and MAPK activation;RUNX2 regulates bone development;Transcriptional regulation by RUNX2;RAF activation;Notch;Regulation of RUNX3 expression and activity;Disease;Negative regulation of FGFR3 signaling;Signaling by FGFR3;Signal Transduction;Recycling pathway of L1;Gene expression (Transcription);Negative regulation of FGFR4 signaling;Signaling by FGFR4;Signaling by FGFR;Transcriptional regulation by RUNX3;Spry regulation of FGF signaling;erk and pi-3 kinase are necessary for collagen binding in corneal epithelia;Vesicle-mediated transport;links between pyk2 and map kinases;regulation of splicing through sam68;ucalpain and friends in cell spread;angiotensin ii mediated activation of jnk pathway via pyk2 dependent signaling;integrin signaling pathway;pelp1 modulation of estrogen receptor activity;phospholipids as signalling intermediaries;vegf hypoxia and angiogenesis;VEGFA-VEGFR2 Pathway;gamma-aminobutyric acid receptor life cycle pathway;how progesterone initiates the oocyte maturation;sprouty regulation of tyrosine kinase signals;cbl mediated ligand-induced downregulation of egf receptors pathway;Membrane Trafficking;calcium signaling by hbx of hepatitis b virus;erk1/erk2 mapk signaling pathway;Generic Transcription Pathway;Prolactin;Alpha6Beta4Integrin;B cell receptor signaling;GPCR Adenosine A2A receptor;CD28 co-stimulation;CTLA4 inhibitory signaling;Costimulation by the CD28 family;Signaling by PDGF;CLEC7A (Dectin-1) signaling;C-type lectin receptors (CLRs);RNA Polymerase II Transcription;GRB2:SOS provides linkage to MAPK signaling for Integrins ;p130Cas linkage to MAPK signaling for integrins;Integrin alphaIIb beta3 signaling;HGF;EPH-Ephrin signaling;TCR;EPHA-mediated growth cone collapse;Oncostatin_M;Innate Immune System;Immune System;EPHB-mediated forward signaling;Ghrelin;Ephrin signaling;Cyclin D associated events in G1;G1 Phase;EPH-ephrin mediated repulsion of cells;Adaptive Immune System;c-src mediated regulation of Cx43 function and closure of gap junctions;KitReceptor;Fibroblast growth factor-1;RHO GTPases Activate Formins;Mitotic G1-G1/S phases;GP1b-IX-V activation signalling;Receptor Mediated Mitophagy;Mitophagy;AndrogenReceptor;roles of arrestin dependent recruitment of src kinases in gpcr signaling;Thrombin signalling through proteinase activated receptors (PARs);Signaling by EGFR;Platelet Aggregation (Plug Formation);cell to cell adhesion signaling;p38MAPK events;Signalling to RAS;Platelet activation, signaling and aggregation;IL-7 signaling;GPCR signaling-G alpha s PKA and ERK;Regulation of KIT signaling;RHO GTPase Effectors;Signaling by Rho GTPases;Signalling to ERKs;DCC mediated attractive signaling;Signaling by NTRK1 (TRKA);Integrin;Netrin mediated repulsion signals;role of nicotinic acetylcholine receptors in the regulation of apoptosis;Activated NTRK2 signals through FYN;Signaling by NTRK2 (TRKB);Signaling by NTRKs;EGFR1;agrin in postsynaptic differentiation;Integrin signaling;PECAM1 interactions;CXCR4-mediated signaling events;ErbB1 downstream signaling;Cell surface interactions at the vascular wall;Hemostasis;GAB1 signalosome;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;Signaling events mediated by TCPTP;Thromboxane A2 receptor signaling;PIP3 activates AKT signaling;JAK STAT pathway and regulation;NCAM signaling for neurite out-growth;E-cadherin signaling in keratinocytes;Posttranslational regulation of adherens junction stability and dissassembly;EPO signaling;Netrin-1 signaling;Signaling events regulated by Ret tyrosine kinase;Downstream signal transduction;Ephrin B reverse signaling;Class I PI3K signaling events;PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling;Negative regulation of the PI3K/AKT network;Signaling by VEGF;L1CAM interactions;RET signaling;Axon guidance;Signaling by SCF-KIT;Leptin;Constitutive Signaling by Aberrant PI3K in Cancer;Signaling by ERBB2;Regulation of RUNX1 Expression and Activity;PI3K/AKT Signaling in Cancer;Cell Cycle;TNFalpha;MET activates PTK2 signaling;MET promotes cell motility;Signaling by MET;Signaling by Receptor Tyrosine Kinases;Signal regulatory protein family interactions;Signaling by RAS mutants;VEGF;Signaling by high-kinase activity BRAF mutants;Cell-Cell communication;Cell Cycle, Mitotic;Regulation of gap junction activity;Gap junction trafficking and regulation;Signaling by moderate kinase activity BRAF mutants;Paradoxical activation of RAF signaling by kinase inactive BRAF;ErbB2/ErbB3 signaling events;Intracellular signaling by second messengers;Osteopontin-mediated events;Transcriptional regulation by RUNX1;Nectin adhesion pathway;Alpha9 beta1 integrin signaling events;LPA receptor mediated events;Signaling by BRAF and RAF fusions;Oncogenic MAPK signaling;Diseases of signal transduction;CDC42 signaling events;Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met);Glypican 1 network;Internalization of ErbB1;Netrin-mediated signaling events;Signaling events mediated by focal adhesion kinase;S1P3 pathway;Regulation of p38-alpha and p38-beta;CXCR3-mediated signaling events;EPHB forward signaling;Regulation of Androgen receptor activity;Arf6 signaling events;Plasma membrane estrogen receptor signaling;FAS (CD95) signaling pathway;Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling;Nongenotropic Androgen signaling;Alpha-synuclein signaling;Alpha4 beta1 integrin signaling events;Class I PI3K signaling events mediated by Akt;Trk receptor signaling mediated by PI3K and PLC-gamma;PDGFR-beta signaling pathway;Signaling events mediated by PTP1B;EPHA2 forward signaling;Endothelins;FGF signaling pathway;Signaling events mediated by VEGFR1 and VEGFR2;Integrins in angiogenesis;Atypical NF-kappaB pathway;E-cadherin signaling in the nascent adherens junction;EPHA forward signaling;Syndecan-2-mediated signaling events;Signaling events mediated by PRL;Syndecan-3-mediated signaling events;VEGFR2 mediated cell proliferation;Negative regulation of FGFR1 signaling;Signaling by FGFR1
(Consensus)
Recessive Scores
- pRec
- 0.995
Intolerance Scores
- loftool
- 0.0217
- rvis_EVS
- -0.69
- rvis_percentile_EVS
- 14.97
Haploinsufficiency Scores
- pHI
- 0.999
- hipred
- Y
- hipred_score
- 0.825
- ghis
- 0.667
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.935
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Src
- Phenotype
- skeleton phenotype; immune system phenotype; vision/eye phenotype; limbs/digits/tail phenotype; neoplasm; pigmentation phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; cellular phenotype; craniofacial phenotype; endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype;
Zebrafish Information Network
- Gene name
- src
- Affected structure
- ceratobranchial cartilage
- Phenotype tag
- abnormal
- Phenotype quality
- morphology
Gene ontology
- Biological process
- primary ovarian follicle growth;stimulatory C-type lectin receptor signaling pathway;cell cycle;signal transduction;transmembrane receptor protein tyrosine kinase signaling pathway;signal complex assembly;epidermal growth factor receptor signaling pathway;transforming growth factor beta receptor signaling pathway;integrin-mediated signaling pathway;axon guidance;cell population proliferation;response to mechanical stimulus;response to virus;response to acidic pH;regulation of epithelial cell migration;positive regulation of epithelial cell migration;positive regulation of platelet-derived growth factor receptor signaling pathway;positive regulation of glucose metabolic process;positive regulation of protein processing;positive regulation of phosphatidylinositol 3-kinase signaling;positive regulation of smooth muscle cell migration;viral process;macroautophagy;peptidyl-serine phosphorylation;peptidyl-tyrosine phosphorylation;regulation of cell-cell adhesion;cell differentiation;platelet activation;forebrain development;T cell costimulation;protein destabilization;response to nutrient levels;positive regulation of protein autophosphorylation;activation of protein kinase B activity;negative regulation of telomere maintenance via telomerase;negative regulation of protein homooligomerization;cellular response to insulin stimulus;regulation of intracellular estrogen receptor signaling pathway;positive regulation of integrin activation;adherens junction organization;substrate adhesion-dependent cell spreading;cellular response to reactive oxygen species;intracellular signal transduction;entry of bacterium into host cell;osteoclast development;cellular response to platelet-derived growth factor stimulus;peptidyl-tyrosine autophosphorylation;Fc-gamma receptor signaling pathway involved in phagocytosis;response to hydrogen peroxide;positive regulation of apoptotic process;negative regulation of apoptotic process;regulation of vascular permeability;stress fiber assembly;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;regulation of protein binding;positive regulation of MAP kinase activity;positive regulation of phosphatidylinositol 3-kinase activity;transcytosis;regulation of bone resorption;bone resorption;positive regulation of cyclin-dependent protein serine/threonine kinase activity;negative regulation of transcription, DNA-templated;positive regulation of transcription, DNA-templated;positive regulation of insulin receptor signaling pathway;protein autophosphorylation;phosphatidylinositol phosphorylation;vascular endothelial growth factor receptor signaling pathway;neurotrophin TRK receptor signaling pathway;ephrin receptor signaling pathway;oogenesis;positive regulation of cytokine secretion;positive regulation of peptidyl-tyrosine phosphorylation;progesterone receptor signaling pathway;leukocyte migration;positive regulation of small GTPase mediated signal transduction;response to mineralocorticoid;response to electrical stimulus;negative regulation of focal adhesion assembly;positive regulation of protein kinase B signaling;negative regulation of mitochondrial depolarization;negative regulation of telomerase activity;uterus development;branching involved in mammary gland duct morphogenesis;regulation of cell projection assembly;positive regulation of ERK1 and ERK2 cascade;response to interleukin-1;cellular response to lipopolysaccharide;cellular response to peptide hormone stimulus;cellular response to progesterone stimulus;cellular response to fatty acid;cellular response to hypoxia;cellular response to fluid shear stress;positive regulation of podosome assembly;positive regulation of protein serine/threonine kinase activity;angiotensin-activated signaling pathway involved in heart process;positive regulation of canonical Wnt signaling pathway;cell-cell adhesion;regulation of postsynaptic neurotransmitter receptor activity;positive regulation of protein localization to nucleus;positive regulation of non-membrane spanning protein tyrosine kinase activity;positive regulation of ovarian follicle development;positive regulation of lamellipodium morphogenesis;positive regulation of DNA biosynthetic process;regulation of early endosome to late endosome transport;negative regulation of anoikis;negative regulation of extrinsic apoptotic signaling pathway;negative regulation of intrinsic apoptotic signaling pathway;regulation of caveolin-mediated endocytosis
- Cellular component
- podosome;nucleus;cytoplasm;mitochondrion;mitochondrial inner membrane;lysosome;late endosome;cytosol;actin filament;plasma membrane;caveola;postsynaptic density;extrinsic component of cytoplasmic side of plasma membrane;ruffle membrane;neuron projection;perinuclear region of cytoplasm;extracellular exosome;glutamatergic synapse;postsynaptic specialization, intracellular component
- Molecular function
- protein kinase activity;protein tyrosine kinase activity;non-membrane spanning protein tyrosine kinase activity;SH3/SH2 adaptor activity;protein kinase C binding;signaling receptor binding;insulin receptor binding;integrin binding;protein binding;ATP binding;protein C-terminus binding;kinase activity;enzyme binding;kinase binding;heme binding;estrogen receptor binding;ubiquitin protein ligase binding;SH2 domain binding;ion channel binding;cadherin binding;ephrin receptor binding;phosphatidylinositol-4,5-bisphosphate 3-kinase activity;phosphoprotein binding;growth factor receptor binding;connexin binding;scaffold protein binding